In an SEC filing, AbbVie ABBV has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per ...

Recently AbbVie closed its acquisition of Aliada Therapeutics, including a promising Alzheimer's disease candidate, for $1.4 ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

AbbVie (ABBV) announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie. TipRanks is the most comprehensive ...

The transaction comes less than two months after AbbVie agreed to pay $1.4 billion in cash to acquire Aliada Therapeutics, a Boston-based biotech that’s developing treatments for central nervous ...

ALIA-1758 is under clinical development by Aliada Therapeutics and currently in Phase I for Alzheimer's Disease.

AbbVie announced the completion of its acquisition of Aliada Therapeutics. 1 As a result, Aliada’s lead investigational asset, ALIA-1758, is an Alzheimer’s treatment that’s in Phase 1 trials and will ...

Dec. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.